Can I Continue to Work With My Primary Care Physician While Using Calibrate?

How Calibrate's Medical Model Works

Calibrate is a telehealth program built around GLP-1 receptor agonists, primarily semaglutide (Ozempic, Wegovy) and, in some cases, liraglutide (Saxenda). The program pairs that pharmacotherapy with one-on-one video coaching across four behavioral pillars: food, sleep, exercise, and emotional health. A Calibrate-affiliated physician reviews your intake history and lab values, then prescribes and titrates the GLP-1 medication over the course of the program.

That physician role is deliberately narrow. Calibrate's clinicians are not positioned as your primary medical home. They do not manage your blood pressure medications, your thyroid disease, your annual wellness exam, or your specialist referrals. Their clinical attention stays on your metabolic health trajectory and the GLP-1 prescription.

What Calibrate Physicians Actually Prescribe and Monitor

Calibrate physicians follow a structured titration schedule. For semaglutide, the standard escalation mirrors the schedule validated in the STEP clinical trial series: starting at 0.25 mg weekly, advancing in 4-week steps toward the target dose of 2.4 mg weekly for weight management or 1 mg weekly for glycemic control. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight reduction at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo (P<0.001), establishing the efficacy profile Calibrate's program is built around. [1]

Calibrate also requires baseline laboratory work before the first prescription, typically including a comprehensive metabolic panel, HbA1c, fasting lipids, and thyroid-stimulating hormone. These labs can be drawn at your PCP's office or through a Calibrate-affiliated lab service.

What Calibrate Does Not Cover

Calibrate does not provide urgent or emergent care. The program does not manage non-metabolic chronic conditions, write referrals to cardiologists or endocrinologists, or handle prescription renewals for medications outside the GLP-1 program. If you develop a new medical problem during the program, your PCP or urgent care is the correct first contact.

Why Keeping Your PCP Is Not Optional, It Is Medically Advisable

Short answer: your PCP holds your longitudinal health record. That context matters for GLP-1 safety.

GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). The FDA label for semaglutide (Wegovy) carries a black-box warning on this point. [2] Your PCP is far more likely than a telehealth intake form to surface a relevant family cancer history, a borderline-low eGFR that affects dosing decisions, or a prior episode of acute pancreatitis that makes GLP-1 therapy higher risk.

The American Diabetes Association's 2024 Standards of Care emphasize individualized therapy decisions that account for comorbidities, concomitant medications, and cardiovascular risk profile. [3] None of that individualization is possible without a clinician who knows your full picture.

Drug-Drug Interactions Your PCP Can Catch

GLP-1 agonists slow gastric emptying. That mechanism can alter the absorption kinetics of oral medications you may already be taking. Oral contraceptives, cyclosporine, levothyroxine, and certain antibiotics are among the drugs whose peak plasma concentrations can shift. A PCP who sees your full medication list can spot interactions that a telehealth intake form may miss.

Warfarin is a particularly important case. Patients on warfarin who start a GLP-1 may need more frequent INR monitoring during the titration phase, because changes in food intake and gastric motility can shift anticoagulation control. Your PCP or anticoagulation clinic should know you are starting this class of medication.

Monitoring That Belongs With Your PCP

Calibrate monitors metabolic markers tied to the program. But several monitoring tasks belong with your PCP:

• Blood pressure trend tracking over years, not quarters
• Bone density (DEXA) if rapid weight loss is occurring in postmenopausal women
• Gallstone surveillance, since rapid weight loss increases cholelithiasis risk by approximately 30% according to data from obesity pharmacotherapy trials [4]
• Cardiovascular risk reassessment after significant weight loss changes your Framingham or ASCVD score

Practical Steps for Coordinating the Two Relationships

Coordination does not require elaborate systems. It requires one honest conversation with your PCP and a habit of sharing visit summaries.

Tell Your PCP You Are Starting or Already On a GLP-1

This is the single most important step. Tell your PCP the name of the medication, the dose, and the prescribing physician's contact information. Most PCPs will want to add the GLP-1 to your medication list in their electronic health record. That record flows to every specialist, every urgent care visit, every anesthesiologist reviewing your chart before a procedure.

If your PCP has concerns about the medication, take those seriously. A PCP who flags a potential contraindication is doing exactly what a longitudinal physician should do.

Share Calibrate Visit Notes With Your PCP

After each Calibrate physician check-in, download or screenshot the visit summary and bring it to your next PCP appointment. At minimum, share notes every three months. That cadence keeps your PCP current on your dose, your lab trends, and any side effects you have reported to Calibrate.

Ask Your PCP About Lab Overlap

Both Calibrate and your PCP may order metabolic labs. Coordinate timing to avoid duplicate blood draws. If your PCP already orders an annual comprehensive metabolic panel and HbA1c, those results can often satisfy Calibrate's baseline requirements. Ask Calibrate's care team whether your existing lab results, if recent, will be accepted.

The HealthRX Dual-Provider Coordination Framework (for patients using any telehealth specialty program alongside a PCP):

| Task | Calibrate Physician | Your PCP | |---|---|---| | GLP-1 prescription and titration | Yes | No (unless PCP also prescribes) | | Baseline metabolic labs | Orders or accepts | Can order and share results | | Drug interaction review | Partial (telehealth intake) | Full (complete med list) | | Acute illness management | No | Yes | | Annual wellness exam | No | Yes | | Specialist referrals | No | Yes | | Long-term cardiovascular monitoring | No | Yes | | Gallstone / bone density surveillance | No | Yes | | Visit note documentation | Shares on request | Documents in full EHR |

What If Your PCP Disagrees With the Calibrate Program?

Some PCPs are skeptical of direct-to-consumer telehealth prescribing. That skepticism is not always unfounded, and the disagreement deserves a direct conversation rather than avoidance.

If your PCP believes GLP-1 therapy is not appropriate for your specific health situation, ask them to explain the clinical rationale. Contraindications are real. A prior episode of pancreatitis, a personal history of MTC, a current pregnancy, or a severely compromised kidney function (eGFR <15 mL/min/1.73m²) represent legitimate clinical reasons to pause or avoid GLP-1 therapy.

If your PCP's objection is more philosophical than clinical, you have options. The Endocrine Society's 2023 Obesity Pharmacotherapy Guidelines support GLP-1 receptor agonists for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity, when lifestyle intervention alone has been insufficient. [5] That guideline document is a reasonable starting point for a productive conversation.

When to Consider Switching to a PCP Who Prescribes GLP-1s

If your PCP is unwilling to document GLP-1 therapy in your chart, unwilling to coordinate lab work, and actively opposes the medication based on personal preference rather than your individual clinical situation, you may be better served by a PCP who has experience with obesity medicine. The American Board of Obesity Medicine (ABOM) certifies physicians who have additional training in this area. Searching the ABOM directory for a certified physician in your area is a reasonable next step.

How GLP-1 Programs Like Calibrate Fit Into Broader Obesity Care Guidelines

The clinical evidence base for GLP-1 therapy in metabolic health has grown substantially over the past five years. The SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in non-diabetic adults with overweight or obesity and established cardiovascular disease, with a hazard ratio of 0.80 (95% CI 0.72 to 0.90, P<0.001). [6] That finding means GLP-1 therapy is no longer purely a weight-loss tool; it carries a cardiovascular outcomes benefit that your cardiologist or PCP managing your heart disease should know about.

The 2023 American Heart Association/American College of Cardiology Guideline on Obesity and the Heart explicitly acknowledges GLP-1 receptor agonists as a therapeutic option for patients with cardiovascular risk. [7] Calibrate's program operates within that evidence base, even though the program itself is not an AHA-endorsed product.

What the Evidence Does Not Yet Show

GLP-1 therapy does not yet have 10-year or 20-year safety data. The FDA approval for semaglutide 2.4 mg (Wegovy) was granted in June 2021 based on the STEP trial series, which ran for 68 to 104 weeks. [2] Long-term monitoring, including periodic thyroid ultrasound in patients with nodular disease, liver function in patients with prior non-alcoholic steatohepatitis, and kidney function in patients with CKD, belongs in the hands of a longitudinal physician who will still be your doctor five years from now. That is your PCP, not a telehealth platform.

Insurance, Billing, and the PCP Visit

Calibrate operates on a subscription or program-fee model, separate from traditional insurance billing. Your Calibrate fees do not typically count toward your PCP copay or deductible. Your PCP visits continue to bill through your health insurance exactly as they did before you started the program.

Some patients ask whether their PCP can simply prescribe the GLP-1 and skip the Calibrate program entirely. The answer is yes, if your PCP is comfortable prescribing and your insurance covers the medication. Wegovy's list price is approximately $1,349 per month without insurance coverage. Many commercial insurance plans now cover Wegovy for patients who meet BMI criteria, and Medicare Part D began covering anti-obesity medications in 2025 under the Inflation Reduction Act provisions. [8] A conversation with your PCP and your insurance plan about prior authorization requirements is worth having before assuming Calibrate is the only path to a GLP-1 prescription.

Side Effects to Report to Both Providers

GLP-1 receptor agonists produce a predictable side effect profile. Nausea, vomiting, constipation, and injection-site reactions are the most common. These are typically reported through Calibrate's platform. However, certain symptoms should go directly to your PCP or an emergency department, not a telehealth message queue:

• Severe or persistent abdominal pain radiating to the back (possible pancreatitis; incidence estimated at approximately 0.1% based on pooled STEP trial safety data) [1]
• Neck mass, hoarseness, or difficulty swallowing (possible thyroid concern; trigger the black-box warning evaluation)
• Sudden onset of jaundice or right upper quadrant pain (possible cholelithiasis or cholecystitis)
• Hypoglycemia symptoms in patients also taking sulfonylureas or insulin

The FDA MedWatch database tracks adverse events from approved medications, and your PCP can file a MedWatch report if a serious adverse event occurs. [9] Calibrate's clinical team should be notified simultaneously, but your PCP is better positioned to initiate a diagnostic workup.

A Note on Mental Health and Behavioral Support

Calibrate's coaching model addresses emotional health as one of its four pillars. However, coaching is not therapy. If you are experiencing clinical depression, an eating disorder, or significant anxiety during the program, those conditions require evaluation by a licensed mental health professional. Your PCP is usually the first referral point for mental health care and can connect you to a psychiatrist, psychologist, or therapist covered by your insurance.

Binge eating disorder (BED) deserves specific mention. GLP-1 agonists may reduce binge eating behaviors through appetite suppression, and early data are promising, but BED remains a psychiatric diagnosis requiring structured treatment. The National Eating Disorders Association recommends formal clinical assessment before starting pharmacotherapy in patients with suspected BED. [10] Your PCP can complete that assessment or provide the appropriate referral.